mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis

The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mT...

Full description

Saved in:
Bibliographic Details
Published inMedical oncology (Northwood, London, England) Vol. 27; no. 4; pp. 1239 - 1245
Main Authors Zhou, Quan, Deng, Zhansheng, Zhu, Yong, Long, Haitao, Zhang, Shaoxian, Zhao, Jiali
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.12.2010
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients’ prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.
AbstractList The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.[PUBLICATION ABSTRACT]
The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.
The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells ( greater than or equal to 90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.
The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.
Author Zhou, Quan
Zhao, Jiali
Deng, Zhansheng
Long, Haitao
Zhang, Shaoxian
Zhu, Yong
Author_xml – sequence: 1
  givenname: Quan
  surname: Zhou
  fullname: Zhou, Quan
  organization: Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College
– sequence: 2
  givenname: Zhansheng
  surname: Deng
  fullname: Deng, Zhansheng
  email: wuque1@hotmail.com
  organization: Department of Spinal Surgery, Xiangya Hospital, Central South University
– sequence: 3
  givenname: Yong
  surname: Zhu
  fullname: Zhu, Yong
  organization: Department of Orthopaedics, Xiangya Hospital, Central South University
– sequence: 4
  givenname: Haitao
  surname: Long
  fullname: Long, Haitao
  organization: Department of Orthopaedics, Xiangya Hospital, Central South University
– sequence: 5
  givenname: Shaoxian
  surname: Zhang
  fullname: Zhang, Shaoxian
  organization: Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College
– sequence: 6
  givenname: Jiali
  surname: Zhao
  fullname: Zhao, Jiali
  organization: Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19936974$$D View this record in MEDLINE/PubMed
BookMark eNp9kdtqFTEUhoNU7EEfwBsZvNGbsTlMMrMupXjCQsFW8C5kMpltykyyzcpQ9p2v4ev5JGbcVaFgrxLI960V_v-YHIQYHCFPGX3FKG1PkXEqeE0p1CCUrHcPyBGTEmom2JeDcheyralU9JAcI15Typnk8IgcMig8tM0R8fPVxafTbUsv1cfq0m-CmaqcTMBhsdnHUG1N_npjdpWNISffL9lhlWMVMbuIJtk4m2qb4iY5xJU3YVgd70LGn99__H4LET0-Jg9HM6F7cnuekM9v31ydva_PL959OHt9XttGQa47agcwzdjzxraCWzEAgLMwCjoaaZhsuQGjetV3Y0-dE1wMDXSKKesodJ04IS_2c8vmb4vDrGeP1k2TCS4uqDvGSy6SreTLe0lGQTSq5R0U9Pkd9DouqYSFGjgrZfBmhZ7dQks_u0Fvk59N2uk_aReg3QM2RcTkRm19NmvMJXI_lYV67VXve9WlV732qnfFZHfMv8PvcfjewcKGjUv__vx_6ReU67be
CODEN MONCEZ
CitedBy_id crossref_primary_10_1016_j_canlet_2016_12_012
crossref_primary_10_1002_ijc_28933
crossref_primary_10_1073_pnas_1419260111
crossref_primary_10_1016_j_biopha_2017_08_116
crossref_primary_10_1093_annonc_mdx709
crossref_primary_10_3389_fonc_2019_00390
crossref_primary_10_1038_tpj_2016_45
crossref_primary_10_1158_1078_0432_CCR_12_2293
crossref_primary_10_3389_pore_2022_1610231
crossref_primary_10_1002_cncr_26617
crossref_primary_10_1158_1535_7163_MCT_19_0689
crossref_primary_10_1016_j_abb_2013_04_001
crossref_primary_10_1093_annonc_mdx536
crossref_primary_10_1016_j_jaad_2013_04_027
crossref_primary_10_1155_2013_480713
crossref_primary_10_3390_cancers12113097
crossref_primary_10_1038_s41419_022_05401_8
crossref_primary_10_1158_1078_0432_CCR_21_0315
crossref_primary_10_2147_OTT_S249477
crossref_primary_10_1002_pbc_28072
crossref_primary_10_18632_oncotarget_10389
crossref_primary_10_1155_2011_460650
crossref_primary_10_1158_0008_5472_CAN_10_0578
crossref_primary_10_1517_14728214_2015_1051965
crossref_primary_10_1016_j_path_2011_07_015
crossref_primary_10_1136_jclinpath_2020_206505
crossref_primary_10_3390_cells9040968
crossref_primary_10_18632_genesandcancer_91
crossref_primary_10_3390_ijms17040506
crossref_primary_10_1186_s41016_019_0162_y
crossref_primary_10_1186_s12935_020_01342_4
crossref_primary_10_3389_fendo_2015_00074
crossref_primary_10_1002_cbin_10075
crossref_primary_10_1038_s41419_023_05910_0
crossref_primary_10_3892_ijmm_2024_5393
crossref_primary_10_1038_nrendo_2017_16
crossref_primary_10_3390_cells10051240
crossref_primary_10_1073_pnas_1420596111
crossref_primary_10_1038_srep09604
crossref_primary_10_31083_j_fbl2704122
crossref_primary_10_3892_ol_2014_1935
crossref_primary_10_3390_cancers14143503
crossref_primary_10_1016_j_bbrc_2018_02_050
crossref_primary_10_1016_j_annpat_2011_10_009
crossref_primary_10_1038_s41420_022_00838_4
crossref_primary_10_1517_21678707_2014_917951
crossref_primary_10_3892_or_2016_4922
crossref_primary_10_1186_s41065_021_00174_0
crossref_primary_10_1177_03009858231207021
crossref_primary_10_1186_s13018_018_0860_8
Cites_doi 10.1038/sj.onc.1209691
10.1002/cncr.22677
10.1016/j.ctrv.2006.05.005
10.1016/j.ceb.2005.02.008
10.1038/nm1052
10.1158/1078-0432.CCR-04-0969
10.1267/ahc.06005
10.1016/j.canlet.2007.01.026
10.1158/1078-0432.CCR-05-1654
10.1126/science.1066015
10.1038/sj.bjc.6600201
10.1002/ijc.21932
10.1093/jnci/92.15.1252
10.1042/BST0320393
10.1073/pnas.171301998
10.1038/ng1494
10.1007/BF00625047
10.1080/00313020802436808
10.1016/j.critrevonc.2004.09.009
10.1586/14737140.6.7.1075
10.1186/1477-7800-3-7
10.1186/1471-2164-9-348
10.1158/0008-5472.CAN-05-3830
10.1016/j.molmed.2005.06.007
10.1097/01.cad.0000173476.67239.3b
10.1097/00003086-198011000-00013
10.1016/j.suronc.2009.09.002
10.1042/bst0320393
ContentType Journal Article
Copyright Springer Science+Business Media, LLC 2009
Springer Science+Business Media, LLC 2010
Copyright_xml – notice: Springer Science+Business Media, LLC 2009
– notice: Springer Science+Business Media, LLC 2010
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7QP
7X8
DOI 10.1007/s12032-009-9365-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE

Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1559-131X
EndPage 1245
ExternalDocumentID 2584253511
19936974
10_1007_s12032_009_9365_y
Genre Journal Article
Feature
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
2.D
203
28-
29M
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
3V.
4.4
406
408
40E
53G
5GY
5RE
5VS
6NX
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABUWG
ABWNU
ABXPI
ACAOD
ACCUX
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GRRUI
H13
HF~
HG6
HMCUK
HMJXF
HRMNR
HVGLF
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXD
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NDZJH
NF0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OVD
P19
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
PZZ
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
Z7U
Z82
Z87
Z8O
Z8V
Z91
ZMTXR
ZOVNA
ZXP
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7QP
7X8
ID FETCH-LOGICAL-c469t-80cd9a4fb24c732c3d999ec9f30fa5a1572a9a6b6b8fb0ee323d498616ce09883
IEDL.DBID U2A
ISSN 1357-0560
1559-131X
IngestDate Tue Aug 05 11:04:55 EDT 2025
Thu Aug 07 15:09:46 EDT 2025
Fri Aug 15 22:51:29 EDT 2025
Mon Jul 21 05:55:49 EDT 2025
Thu Apr 24 23:06:26 EDT 2025
Tue Jul 01 01:49:02 EDT 2025
Fri Feb 21 02:33:48 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Prognosis
p70 S6 kinase
Osteosarcoma
Clinical pathology
Mammalian target of rapamycin
Language English
License http://www.springer.com/tdm
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c469t-80cd9a4fb24c732c3d999ec9f30fa5a1572a9a6b6b8fb0ee323d498616ce09883
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-2
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 19936974
PQID 921100249
PQPubID 30753
PageCount 7
ParticipantIDs proquest_miscellaneous_812135518
proquest_miscellaneous_1093467289
proquest_journals_921100249
pubmed_primary_19936974
crossref_citationtrail_10_1007_s12032_009_9365_y
crossref_primary_10_1007_s12032_009_9365_y
springer_journals_10_1007_s12032_009_9365_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-12-01
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 2010-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Boston
PublicationPlace_xml – name: Boston
– name: United States
– name: Middlesex
PublicationTitle Medical oncology (Northwood, London, England)
PublicationTitleAbbrev Med Oncol
PublicationTitleAlternate Med Oncol
PublicationYear 2010
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Kaya, Wada, Kawaguchi (CR19) 2002; 86
Majumder (CR24) 2004; 10
Inoki, Corradetti, Guan (CR7) 2005; 37
Liu (CR12) 2006; 25
Harada, Andersen, Mann, Terada, Korsmeyer (CR26) 2001; 98
Heinonen, Nieminen, Saarela, Kallioniemi, Klefström, Hautaniemi (CR14) 2008; 9
Guertin, Sabatini (CR8) 2005; 11
Fang, Vilella-Bach, Bachmann, Flanigan, Chen (CR22) 2001; 294
Couch (CR11) 1999; 59
Hou, Xue, Lu, Fan, Tian, Xue (CR28) 2007; 253
Pantuck, Seligson, Klatte (CR17) 2007; 109
Mungamuri, Yang, Thor, Somasundaram (CR23) 2006; 66
Enneking, Spanier, Goodman (CR15) 1980; 153
Morgensztern, McLeod (CR25) 2005; 16
Ek, Ojaimi, Kitagawa, Choong (CR3) 2006; 3
Chou, Gorlick (CR2) 2006; 6
Kreuter, Bieker, Bielack (CR18) 2004; 10
CR5
Workman (CR20) 2004; 32
Salzer-Kuntschik, Delling, Beron, Sigmund (CR16) 1983; 106
Osaka, Suzuki, Osaka, Yoshida, Sugita, Asami (CR6) 2006; 39
Longhi, Errani, De Paolis (CR1) 2006; 32
Granville, Memmot, Gills, Dennis (CR21) 2006; 12
Beevers, Li, Liu, Huang (CR27) 2006; 119
Law (CR10) 2005; 56
Huang, Zhu, Lu, Lian, Wang, Yang (CR4) 2009; 41
Bärlund (CR13) 2000; 92
Martin, Hall (CR9) 2005; 17
SK Mungamuri (9365_CR23) 2006; 66
K Inoki (9365_CR7) 2005; 37
DA Guertin (9365_CR8) 2005; 11
M Salzer-Kuntschik (9365_CR16) 1983; 106
FJ Couch (9365_CR11) 1999; 59
AJ Pantuck (9365_CR17) 2007; 109
BK Law (9365_CR10) 2005; 56
G Hou (9365_CR28) 2007; 253
M Kaya (9365_CR19) 2002; 86
ETH Ek (9365_CR3) 2006; 3
L Liu (9365_CR12) 2006; 25
CA Granville (9365_CR21) 2006; 12
M Bärlund (9365_CR13) 2000; 92
CS Beevers (9365_CR27) 2006; 119
P Workman (9365_CR20) 2004; 32
PK Majumder (9365_CR24) 2004; 10
DE Martin (9365_CR9) 2005; 17
WF Enneking (9365_CR15) 1980; 153
AJ Chou (9365_CR2) 2006; 6
D Morgensztern (9365_CR25) 2005; 16
A Longhi (9365_CR1) 2006; 32
Y Fang (9365_CR22) 2001; 294
H Harada (9365_CR26) 2001; 98
H Heinonen (9365_CR14) 2008; 9
E Osaka (9365_CR6) 2006; 39
M Kreuter (9365_CR18) 2004; 10
9365_CR5
J Huang (9365_CR4) 2009; 41
11729323 - Science. 2001 Nov 30;294(5548):1942-5
15156201 - Nat Med. 2004 Jun;10(6):594-601
15624019 - Nat Genet. 2005 Jan;37(1):19-24
16651424 - Cancer Res. 2006 May 1;66(9):4715-24
16096426 - Anticancer Drugs. 2005 Sep;16(8):797-803
10922410 - J Natl Cancer Inst. 2000 Aug 2;92(15):1252-9
6577010 - J Cancer Res Clin Oncol. 1983;106 Suppl:21-4
17327929 - Acta Histochem Cytochem. 2006 Jul 1;39(3):95-100
11493700 - Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
7449206 - Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20
16039868 - Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60
15046615 - Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6
15780592 - Curr Opin Cell Biol. 2005 Apr;17(2):158-66
10197603 - Cancer Res. 1999 Apr 1;59(7):1408-11
18972316 - Pathology. 2009 Feb;41(2):149-54
15623635 - Clin Cancer Res. 2004 Dec 15;10(24):8531-7
17440983 - Cancer. 2007 Jun 1;109 (11):2257-67
16002336 - Trends Mol Med. 2005 Aug;11(8):353-61
16467077 - Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89
16551370 - Int Semin Surg Oncol. 2006 Mar 21;3:7
17360108 - Cancer Lett. 2007 Aug 18;253(2):236-48
19836228 - Surg Oncol. 2011 Mar;20(1):13-9
16831079 - Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85
11953816 - Br J Cancer. 2002 Mar 18;86(6):864-9
16550606 - Int J Cancer. 2006 Aug 15;119(4):757-64
18652687 - BMC Genomics. 2008 Jul 24;9:348
16860938 - Cancer Treat Rev. 2006 Oct;32(6):423-36
16715128 - Oncogene. 2006 Nov 9;25(53):7029-40
References_xml – volume: 25
  start-page: 7029
  year: 2006
  end-page: 7040
  ident: CR12
  article-title: Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209691
– volume: 109
  start-page: 2257
  year: 2007
  end-page: 2267
  ident: CR17
  article-title: Prognostic relevance of the mTOR pathway in renal cell carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.22677
– volume: 32
  start-page: 423
  year: 2006
  end-page: 436
  ident: CR1
  article-title: Primary bone osteosarcoma in the pediatric age: state of the art
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2006.05.005
– volume: 17
  start-page: 158
  year: 2005
  end-page: 166
  ident: CR9
  article-title: The expanding TOR signaling network
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/j.ceb.2005.02.008
– volume: 10
  start-page: 594
  year: 2004
  end-page: 601
  ident: CR24
  article-title: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
  publication-title: Nat Med
  doi: 10.1038/nm1052
– volume: 153
  start-page: 106
  year: 1980
  end-page: 120
  ident: CR15
  article-title: A system for the surgical staging of musculoskeletal sarcoma
  publication-title: Clin Orthop Relat Res
– volume: 10
  start-page: 8531
  year: 2004
  end-page: 8537
  ident: CR18
  article-title: Prognostic relevance of increased angiogenesis in osteosarcoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0969
– volume: 39
  start-page: 95
  year: 2006
  end-page: 100
  ident: CR6
  article-title: Survivin as a prognostic factor for osteosarcoma patient
  publication-title: Acta Histochem Cytochem
  doi: 10.1267/ahc.06005
– volume: 253
  start-page: 236
  year: 2007
  end-page: 248
  ident: CR28
  article-title: An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2007.01.026
– volume: 12
  start-page: 679
  year: 2006
  end-page: 689
  ident: CR21
  article-title: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-1654
– volume: 294
  start-page: 1942
  year: 2001
  end-page: 1945
  ident: CR22
  article-title: Phosphatidic acid-mediated mitogenic activation of mTOR signaling
  publication-title: Science
  doi: 10.1126/science.1066015
– volume: 86
  start-page: 864
  year: 2002
  end-page: 869
  ident: CR19
  article-title: Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6600201
– volume: 59
  start-page: 1408
  year: 1999
  end-page: 1411
  ident: CR11
  article-title: Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer
  publication-title: Cancer Res
– volume: 119
  start-page: 757
  year: 2006
  end-page: 764
  ident: CR27
  article-title: Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21932
– volume: 92
  start-page: 1252
  year: 2000
  end-page: 1259
  ident: CR13
  article-title: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.15.1252
– volume: 32
  start-page: 393
  year: 2004
  end-page: 396
  ident: CR20
  article-title: Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment
  publication-title: Biochem Soc Trans
  doi: 10.1042/BST0320393
– volume: 98
  start-page: 9666
  year: 2001
  end-page: 9670
  ident: CR26
  article-title: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.171301998
– volume: 37
  start-page: 19
  year: 2005
  end-page: 24
  ident: CR7
  article-title: Dysregulation of the TSC-mTOR pathway in human disease
  publication-title: Nat Genet
  doi: 10.1038/ng1494
– volume: 106
  start-page: 21
  issue: Suppl
  year: 1983
  end-page: 24
  ident: CR16
  article-title: Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/BF00625047
– volume: 41
  start-page: 149
  year: 2009
  end-page: 54
  ident: CR4
  article-title: The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis
  publication-title: Pathology
  doi: 10.1080/00313020802436808
– volume: 56
  start-page: 47
  year: 2005
  end-page: 60
  ident: CR10
  article-title: Rapamycin: an anti-cancer immunosuppressant?
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2004.09.009
– ident: CR5
– volume: 6
  start-page: 1075
  year: 2006
  end-page: 1085
  ident: CR2
  article-title: Chemotherapy resistance in osteosarcoma: current challenges and future directions
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1586/14737140.6.7.1075
– volume: 3
  start-page: 7
  year: 2006
  end-page: 18
  ident: CR3
  article-title: Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival?
  publication-title: Int Semin Surg Oncol
  doi: 10.1186/1477-7800-3-7
– volume: 9
  start-page: 348
  year: 2008
  end-page: 359
  ident: CR14
  article-title: Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-9-348
– volume: 66
  start-page: 4715
  year: 2006
  end-page: 4724
  ident: CR23
  article-title: Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3830
– volume: 11
  start-page: 353
  year: 2005
  end-page: 361
  ident: CR8
  article-title: An expanding role for mTOR in cancer
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2005.06.007
– volume: 16
  start-page: 797
  year: 2005
  end-page: 803
  ident: CR25
  article-title: Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy
  publication-title: Anticancer Drugs
  doi: 10.1097/01.cad.0000173476.67239.3b
– volume: 153
  start-page: 106
  year: 1980
  ident: 9365_CR15
  publication-title: Clin Orthop Relat Res
  doi: 10.1097/00003086-198011000-00013
– volume: 86
  start-page: 864
  year: 2002
  ident: 9365_CR19
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6600201
– volume: 12
  start-page: 679
  year: 2006
  ident: 9365_CR21
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-1654
– volume: 98
  start-page: 9666
  year: 2001
  ident: 9365_CR26
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.171301998
– volume: 59
  start-page: 1408
  year: 1999
  ident: 9365_CR11
  publication-title: Cancer Res
– volume: 10
  start-page: 8531
  year: 2004
  ident: 9365_CR18
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0969
– volume: 25
  start-page: 7029
  year: 2006
  ident: 9365_CR12
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209691
– volume: 56
  start-page: 47
  year: 2005
  ident: 9365_CR10
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2004.09.009
– volume: 9
  start-page: 348
  year: 2008
  ident: 9365_CR14
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-9-348
– ident: 9365_CR5
  doi: 10.1016/j.suronc.2009.09.002
– volume: 41
  start-page: 149
  year: 2009
  ident: 9365_CR4
  publication-title: Pathology
  doi: 10.1080/00313020802436808
– volume: 11
  start-page: 353
  year: 2005
  ident: 9365_CR8
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2005.06.007
– volume: 119
  start-page: 757
  year: 2006
  ident: 9365_CR27
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21932
– volume: 109
  start-page: 2257
  year: 2007
  ident: 9365_CR17
  publication-title: Cancer
  doi: 10.1002/cncr.22677
– volume: 39
  start-page: 95
  year: 2006
  ident: 9365_CR6
  publication-title: Acta Histochem Cytochem
  doi: 10.1267/ahc.06005
– volume: 253
  start-page: 236
  year: 2007
  ident: 9365_CR28
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2007.01.026
– volume: 32
  start-page: 423
  year: 2006
  ident: 9365_CR1
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2006.05.005
– volume: 17
  start-page: 158
  year: 2005
  ident: 9365_CR9
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/j.ceb.2005.02.008
– volume: 32
  start-page: 393
  year: 2004
  ident: 9365_CR20
  publication-title: Biochem Soc Trans
  doi: 10.1042/bst0320393
– volume: 66
  start-page: 4715
  year: 2006
  ident: 9365_CR23
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3830
– volume: 6
  start-page: 1075
  year: 2006
  ident: 9365_CR2
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1586/14737140.6.7.1075
– volume: 92
  start-page: 1252
  year: 2000
  ident: 9365_CR13
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.15.1252
– volume: 106
  start-page: 21
  issue: Suppl
  year: 1983
  ident: 9365_CR16
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/BF00625047
– volume: 10
  start-page: 594
  year: 2004
  ident: 9365_CR24
  publication-title: Nat Med
  doi: 10.1038/nm1052
– volume: 294
  start-page: 1942
  year: 2001
  ident: 9365_CR22
  publication-title: Science
  doi: 10.1126/science.1066015
– volume: 3
  start-page: 7
  year: 2006
  ident: 9365_CR3
  publication-title: Int Semin Surg Oncol
  doi: 10.1186/1477-7800-3-7
– volume: 16
  start-page: 797
  year: 2005
  ident: 9365_CR25
  publication-title: Anticancer Drugs
  doi: 10.1097/01.cad.0000173476.67239.3b
– volume: 37
  start-page: 19
  year: 2005
  ident: 9365_CR7
  publication-title: Nat Genet
  doi: 10.1038/ng1494
– reference: 16467077 - Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89
– reference: 10197603 - Cancer Res. 1999 Apr 1;59(7):1408-11
– reference: 17440983 - Cancer. 2007 Jun 1;109 (11):2257-67
– reference: 15156201 - Nat Med. 2004 Jun;10(6):594-601
– reference: 18972316 - Pathology. 2009 Feb;41(2):149-54
– reference: 16550606 - Int J Cancer. 2006 Aug 15;119(4):757-64
– reference: 17360108 - Cancer Lett. 2007 Aug 18;253(2):236-48
– reference: 15780592 - Curr Opin Cell Biol. 2005 Apr;17(2):158-66
– reference: 11493700 - Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
– reference: 16039868 - Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60
– reference: 15623635 - Clin Cancer Res. 2004 Dec 15;10(24):8531-7
– reference: 16002336 - Trends Mol Med. 2005 Aug;11(8):353-61
– reference: 16715128 - Oncogene. 2006 Nov 9;25(53):7029-40
– reference: 18652687 - BMC Genomics. 2008 Jul 24;9:348
– reference: 19836228 - Surg Oncol. 2011 Mar;20(1):13-9
– reference: 16551370 - Int Semin Surg Oncol. 2006 Mar 21;3:7
– reference: 16860938 - Cancer Treat Rev. 2006 Oct;32(6):423-36
– reference: 16096426 - Anticancer Drugs. 2005 Sep;16(8):797-803
– reference: 11953816 - Br J Cancer. 2002 Mar 18;86(6):864-9
– reference: 7449206 - Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20
– reference: 15624019 - Nat Genet. 2005 Jan;37(1):19-24
– reference: 10922410 - J Natl Cancer Inst. 2000 Aug 2;92(15):1252-9
– reference: 11729323 - Science. 2001 Nov 30;294(5548):1942-5
– reference: 15046615 - Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6
– reference: 16651424 - Cancer Res. 2006 May 1;66(9):4715-24
– reference: 16831079 - Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85
– reference: 6577010 - J Cancer Res Clin Oncol. 1983;106 Suppl:21-4
– reference: 17327929 - Acta Histochem Cytochem. 2006 Jul 1;39(3):95-100
SSID ssj0021529
Score 2.1438441
Snippet The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma,...
The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma,...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1239
SubjectTerms Adolescent
Adult
Antibodies
Bone Neoplasms - metabolism
Bone Neoplasms - secondary
Cancer
Cell proliferation
Cell survival
Child
Child, Preschool
Disease Progression
Female
Hematology
Humans
Immunoenzyme Techniques
Immunohistochemistry
Internal Medicine
Male
Medicine
Medicine & Public Health
Metastases
Middle Aged
Multivariate analysis
Neoplasm Staging
Oncology
Original Paper
Osteosarcoma
Osteosarcoma - metabolism
Osteosarcoma - pathology
Pathology
Prognosis
Regression analysis
Ribosomal Protein S6 Kinases, 70-kDa - metabolism
Sarcoma
Signal Transduction
Survival Rate
TOR protein
TOR Serine-Threonine Kinases - metabolism
Young Adult
SummonAdditionalLinks – databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB58XLyI4qu-iCAISrHbpk1yEhFFFBV8wN5KXhVB29VWZP-9mbTbRUQvvSSlYWaSmelMvg9g3xmBjV0kERrGdEgVj0KVGuseVslkkFrq2RpubrPLJ3o1TIddb07dtVVOzkR_UJtK4z_yY4GZCuLbnYzeQySNwuJqx6AxC_OIXIYdXWw4zbecaxI-30pZ6Px8X9T0N-eQOTzEyoDAPq_xT7f0K9b8VSf17udiCRa7uJGctopehhlbrsDz2-Pd_fGIRQ_ZNXl4ecYZDTof02LCEuQb_pJj4hvSkdnK1qSpCF7sqGpn4tWbJL5Dq0XnILI0pENarQ_8SFnVL_UqPF2cP55dhh1zQqhduts4t6ONkLRQMdUsiXViXBxotSiSqJCpHKQslkJmKlO8UJG1SZwYKng2yLSNBOfJGsyVVWk3gHCeMeuSMsYGirpgR0QmlrGMlC44LaQJIJoILtcdrDiyW7zmU0BklHXuZJ2jrPNxAIf9K6MWU-O_yVsTbeTd9qrz3hgC2OtH3b7AYocsbfVZY2U9cU7A5ZMBkD_mcMSzQ0i6ANZbPU_XI5DpkNEAjiaKn37-z8Vu_rvYLViI-2aYbZhrPj7tjgtpGrXrDfcb_-Ty7g
  priority: 102
  providerName: ProQuest
Title mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
URI https://link.springer.com/article/10.1007/s12032-009-9365-y
https://www.ncbi.nlm.nih.gov/pubmed/19936974
https://www.proquest.com/docview/921100249
https://www.proquest.com/docview/1093467289
https://www.proquest.com/docview/812135518
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB7RVkJcEP-khZWROIEiso4T28cFbamoWlDblZZTZDtOtRJNKpKq2huvwevxJMzkb4VKkbgkh0wSazzOzJcZfwPwGo3Ac4wkwlxKFwqrotAmuceDtyaeJl603RqOjtODhfi0TJb9Pu56qHYfUpLtl3qz2Y2afYf0M19TadZ6C3YSgu5oxAs-G1EWOiTdoqxEhujdx1Tm3x7xpzO6EWHeyI62Tmf_Adzvo0U266b3Idzx5SO4e9Tnwx_D6uLs88m7SxmdpofsdHVOwg15n7wjhWXUcPjarFlbkU6trXzNmorRzo6qRhuvLgxrS7Q6eg5mypz1VKv1rx8_22tlVa_qJ7DYn599OAj75gmhQ8TboOdxuTaisFw4GXMX5xgKeqeLOCpMYqaJ5Eab1KZWFTbyPuZxLrRKp6nzkVYqfgrbZVX658CUSqVHXCbl1AqMd3SUc8NNZF2hRGHyAKJBi5nrmcWpwcW3bMOJTIrPUPEZKT5bB_BmvOWyo9X4l_DeMDVZv8LqTBNyJb7DAF6NV3FpUL7DlL66qim5HqMfQEgZALtFRhGlHbHSBfCsm_TNeDQ1O5QigLeDFWxef-tgd_9Leg_u8bE-5gVsN9-v_EuMcho7gS25lBPYmX38ejjH8_v58ZeTSWvrvwHNp_md
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9RADLbK9gAXBOIVWmCQQEigqNnJJJMcEOLRasu2C2q3Um9hXqkq0WRLUlX7o_iP2HmtUNXeesklk2Rke8Z27Pk-gDdoBI5jJOFbKY0vdBL4OrIOL06rcBw50bA17M_iyZH4fhwdr8Hf_iwMtVX2e2KzUdvS0D_yrZQyFcK3-7Q494k0ioqrPYNGaxVTt7zEjK36uPsN1fuW853t-deJ35EK-AYzwRp3ZGNTJXLNhZEhN6HFEMmZNA-DXEVqHEmuUhXrWCe5DpwLeWhFmsTj2LggTZIQ33sH1kWImcwI1r9sz34eDBkeOsO0yfAi6WNkMZRRm7N6xFXuUy0ipc6y5f-O8Ep0e6Uy2zi8nQdwv4tU2efWtB7CmisewcnZ_MfB1kIGh_GUHZ6e0Iia3J1tUWgZMRxfqiVrWuCJS8tVrC4ZHSUpKxRfeaZY0xPW4oEwVVjWYbtW75o7RVmdVo_h6FbE-gRGRVm4Z8CSJJYO00Apx1pgeJUGliuuAm3yROTKehD0gstMB2ROfBq_sxUEM8k6Q1lnJOts6cH74ZFFi-Jx0-CNXhtZt6CrbDA_D14Pd3ElUnlFFa68qKiWH6LbwQzWA3bNmIQQ9AgEz4OnrZ5X80mJW1EKDz70il99_trJPr9xsq_g7mS-v5ft7c6mG3CPD604mzCq_1y4FxhQ1fplZ8YMft32yvkHG-sxmA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB5qBfFFFG-xXlZQBCWcZHPZ7IOU0npoPVrFtnDe0r2lFGxyNCnl_DT_XWdyO0hp3_qSl2ySZXZmZyYz-30A71AJHMdIwrdCGD_WWeDrxDq8OK2iMHFxy9bwfT_dPYq_zpP5GvwbzsJQW-WwJ7Ybta0M_SOfSMpUCN9uUvRdET93ppuLPz4RSFGhdWDT6DRk5pYXmL3Vn_d2cKnfcz79cri96_cEA77BrLDB3dlYqeJC89iIiJvIYrjkjCyioFCJChPBlVSpTnVW6MC5iEc2llkapsYFMssifO8duCuiJCQTE_NVroduUba5XiJ8jDHGgmp7ao9Yy32qSkjqMVv-7xKvxLlXarSt65s-hAd9zMq2OiV7BGuufAwnZ4c_fk0WIjhIZ-zg9IRGNOT4bIdHy4jr-EItWdsMT6xarmZNxehQSVWj8KozxdrusA4ZhKnSsh7ltf7Q3imr-rR-Ake3ItSnsF5WpXsOLMtS4TAhFCLUMQZaMrBccRVoU2RxoawHwSC43PSQ5sSs8TtfgTGTrHOUdU6yzpcefBwfWXR4HjcN3hhWI-9Nu85HRfTg7XgXbZIKLap01XlNVf0IHRDmsh6wa8ZkhKVHcHgePOvWeTUfSSyLIvbg07Dwq89fO9kXN072DdxDe8m_7e3PNuA-H3tyXsJ68_fcvcLIqtGvWx1mcHzbRnMJEUA0aA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=mTOR%2Fp70S6K+Signal+transduction+pathway+contributes+to+osteosarcoma+progression+and+patients%E2%80%99+prognosis&rft.jtitle=Medical+oncology+%28Northwood%2C+London%2C+England%29&rft.au=Zhou%2C+Quan&rft.au=Deng%2C+Zhansheng&rft.au=Zhu%2C+Yong&rft.au=Long%2C+Haitao&rft.date=2010-12-01&rft.issn=1357-0560&rft.eissn=1559-131X&rft.volume=27&rft.issue=4&rft.spage=1239&rft.epage=1245&rft_id=info:doi/10.1007%2Fs12032-009-9365-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12032_009_9365_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1357-0560&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1357-0560&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1357-0560&client=summon